Diagnosis of SLE According to EULAR Criteria
The EULAR/ACR 2019 classification criteria require a positive ANA test at titer ≥1:80 by indirect immunofluorescence on HEp-2 cells as an obligatory entry criterion, followed by accumulation of ≥10 weighted points across 7 clinical and 3 immunologic domains to classify a patient as having SLE. 1, 2
Critical Entry Criterion: Antinuclear Antibodies (ANA)
The most significant change in the EULAR/ACR 2019 criteria is making positive ANA an absolute requirement before any other criteria can be counted 1. This represents a strategic shift from previous classification systems where ANA had equal weight with other autoantibodies.
ANA Testing Requirements:
- Titer threshold: ≥1:80 by indirect immunofluorescence test (IFI) on HEp-2 cells 1, 2
- Sensitivity: 99.5% 3
- Specificity at 1:80: Only 74.7% (95% CI: 66.7-81.3%) 1
Important Caveat About ANA Specificity
Exercise great caution when interpreting ANA at the 1:80 cutoff in clinical practice. This threshold has a low positive likelihood ratio, meaning diagnosis must be primarily based on clinical manifestations rather than the ANA result alone 1. The relatively low specificity reflects that ANA occurs in various systemic rheumatologic disorders and healthy individuals 1.
Clinical Practice Recommendation: If using a 1:160 dilution cutoff instead, specificity increases to 86.2% (95% CI: 80.4-90.5%) while maintaining excellent sensitivity of 95.8% (95% CI: 94.1-97.1%) 1. For patients with ANA titers between 1:80 and 1:160, test anti-ENA antibodies, specifically anti-Ro, to clarify the diagnosis 1.
Weighted Criteria System After ANA Entry
Once ANA positivity is established, patients accumulate points from weighted criteria across domains 2, 4:
Clinical Domains (7 categories):
- Constitutional (fever)
- Hematologic (leukopenia, thrombocytopenia, autoimmune hemolysis)
- Neuropsychiatric (delirium, psychosis, seizure)
- Mucocutaneous (alopecia, oral ulcers, subacute/chronic cutaneous lupus, acute cutaneous lupus)
- Serosal (pleural/pericardial effusion, acute pericarditis)
- Musculoskeletal (joint involvement)
- Renal (proteinuria, renal biopsy showing class II/III/IV/V lupus nephritis)
Immunologic Domains (3 categories):
- Antiphospholipid antibodies (anticardiolipin, anti-β2GP1, lupus anticoagulant)
- Complement proteins (low C3 or C4, low C3 AND C4)
- SLE-specific antibodies (anti-dsDNA, anti-Smith)
Point values range from 2 to 10, with class III or IV lupus nephritis alone scoring 10 points (sufficient for classification) 2, 4.
Critical Attribution Rule
Each criterion must be attributed to SLE and not more likely explained by an alternative diagnosis. 2, 3 This single rule replaces the multiple exclusions in previous criteria and significantly improves specificity. Failure to apply this attribution rule properly is the most common reason for misclassification in external validation studies 5.
Within each domain, only count the highest-weighted item - do not sum multiple items from the same domain 4.
Performance Characteristics
When applied correctly, the EULAR/ACR 2019 criteria achieve 2:
- Sensitivity: 96.1%
- Specificity: 93.4%
- Classification threshold: ≥10 points
This represents optimal balance compared to ACR 1997 criteria (82.8% sensitivity, 93.4% specificity) and SLICC 2012 criteria (96.7% sensitivity, 83.7% specificity) 2.
Common Pitfalls to Avoid
Using these as diagnostic criteria: These are classification criteria designed for research cohorts, not diagnostic criteria for individual patients 1. Clinical judgment incorporating the full clinical picture remains essential.
Ignoring the attribution rule: Items should only be counted if SLE is the most likely explanation, not if another diagnosis better explains the finding 3, 5.
Misunderstanding ANA methods: Solid-phase assays (SPA) may be used if they have "equivalent performance" to IFI, but many clinicians wrongly assume all ANA methods are interchangeable 1. Laboratory reports should specify which method was used 1.
Counting multiple items within one domain: Only the highest-weighted criterion within each domain counts toward the total 4.
Insufficient clinical information: Provide detailed clinical context with laboratory requests so immunology laboratories can properly interpret results and recommend appropriate follow-up testing 1.
Anti-dsDNA Antibodies: The Highest-Weighted Immunologic Criterion
Anti-dsDNA represents the most prominent immunological criterion in the EULAR/ACR 2019 system 1. However, anti-dsDNA is not a uniform entity - it encompasses heterogeneous antibodies targeting multiple DNA structures with varying specificities 1. Anti-dsDNA can occur in healthy individuals, other autoimmune syndromes, infections, and malignancies 1.
Different assays use different antigenic materials (native DNA, plasmid DNA, synthetic DNA), explaining why a patient's serum may show different binding capacities across assays 1. This heterogeneity underscores why the complete criteria set, not isolated antibody results, determines classification.